NCT05616793View on ClinicalTrials.gov

Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

June 15, 2023

Primary Completion Date

June 15, 2028

Study Completion Date

June 15, 2028

Conditions

LCA5

Interventions

BIOLOGICAL

AAV8.hLCA5

Adeno-associated virus vector expressing human LCA5 gene

Trial Locations (1)

19104

RECRUITING

University of Pennsylvania Perelman School of Medicine, Philadelphia

Sponsors

Lead Sponsor

Opus Genetics, Inc

All Listed Sponsors

collaborator

University of Pennsylvania

OTHER

lead

Opus Genetics, Inc

INDUSTRY

NCT05616793 - Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) | Biotech Hunter | Biotech Hunter